Exchange: NASDAQ·Updated 07:40 PM EDT
News
all
press releases
MoonLake's Psoriatic Arthritis Drug Shows Promise In Late-Stage Study
MoonLake Immunotherapeutics (MLTX) announces positive Phase 3 psoriatic arthritis trial results. Cash runway backed through mid-2028.read more...
Benzinga
More News
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’
At week 16, 42.1% of patients on Sonelokimab achieved at least a 50% improvement in psoriatic arthritis symptoms, meeting the trial’s primary endpoint.
Stocktwits
MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
MoonLake has consistently guided for a “mid-2026” primary endpoint readout from IZAR-1, its late-stage trial for sonelokimab in certain patients with active psoriatic arthritis.
Stocktwits
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
The consensus price target hints at a 73.4% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears
SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.
Stocktwits
MoonLake Immunotherapeutics' CFO Sells 39K Shares
Key PointsThe executive sold 39,120 shares on June 22...
Nasdaq News: Markets
MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa
MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa...
Yahoo! Finance: News
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
Key PointsIt aims to raise up to $200 million in the offering...
Nasdaq News: Markets
MLTX Stock Extends Pullback After Biggest Rally In Over 6 Months Following Skin Disease Trial Data — A Look At The Latest Development
The biotech firm upsized its offering to $200 million, up from the previously announced $150 million.
Stocktwits
MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism?
Clear Street described sonelokimab’s profile in hidradenitis suppurativa as highly competitive and one that readily supports “blockbuster potential.”
Stocktwits

Advertisement|Remove ads.